Showing 2683 results
-
Key Release /Net sales grew 6% (cc[1], +3% USD) mainly driven by: Cosentyx grew to USD 750 million (+37% cc) with strong volume growth across indications Entresto more than doubled to USD 271 million (+113…
-
Key Release /Hausse du chiffre d'affaires net de 6% (tcc[1], +3% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 750 millions (+37% tcc) grâce à une forte croissance en volume dans toutes…
-
Key Release /Novartis to acquire Endocyte to accelerate development of innovative radioligand technology for treating cancer Acquisition would add 177Lu-PSMA-617, a potential first-in-class…
-
Press Release /Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
-
Press Release /In SOLAR-1 trial, BYL719 plus fulvestrant significantly improved PFS and ORR in these patients, following progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor, vs.…
-
Press Release /Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
-
Press Release /The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported…
-
Press Release /Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of…
-
Press Release /SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART…
-
Press Release /Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…